Anesthesia choice may influence lung cancer return, major trial investigates
NCT ID NCT06330038
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This large clinical trial is testing whether the type of anesthesia used during lung cancer surgery affects the chances of the cancer coming back. Over 5,000 people having surgery for early-stage non-small cell lung cancer will be randomly assigned to receive either intravenous propofol or inhaled gas anesthesia. The study will track cancer recurrence and survival for years after surgery to see if one method is better.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Propofol and inhaled anesthetics (sevoflurane, desflurane, isoflurane)
- What this could lead to
- If it works, this could show that choosing a specific anesthesia type during lung cancer surgery helps reduce the chance of cancer coming back.
- What could go wrong
- This is a large, late-stage trial, but it's testing a subtle effect—anesthesia type may not significantly impact cancer recurrence. Results may not change standard practice.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANESTHESIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Samsung Medical Center
RECRUITINGSeoul, Seoul-teukbyeolsi, 06351, South Korea
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a smart pump prevent dangerous drops in blood pressure during C-Sections?
- Can a ketamine boost during surgery slash opioid needs?
- Can a new immunotherapy combo outsmart advanced lung cancer?
- Can a wearable glucose sensor survive the operating room?
- Double attack on mutant KRAS: can two targeted drugs outsmart resistant cancers?
- Seeing the fight: new imaging tracer may reveal how immune cells attack lung cancer